Restart Life Sciences Corp. NMLSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.95% | -11.40% | 102.63% | 130.58% | 87.15% |
| Depreciation & Amortization | 628.57% | 153.33% | -25.00% | -23.53% | -22.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.04% | -4.56% | 102.75% | 130.24% | 87.06% |
| Operating Income | -46.28% | 16.54% | -102.75% | -118.67% | -87.22% |
| Income Before Tax | -225.33% | -117.15% | -700.86% | -9,169.79% | 18.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -225.33% | -117.15% | -700.86% | -9,169.79% | 18.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -225.33% | -117.15% | -700.86% | -9,169.79% | 18.06% |
| EBIT | -46.28% | 16.54% | -102.75% | -118.67% | -87.22% |
| EBITDA | -46.25% | 16.60% | -103.20% | -119.31% | -87.64% |
| EPS Basic | -683.33% | -409.68% | -399.09% | -6,100.00% | 90.48% |
| Normalized Basic EPS | 35.39% | 58.40% | 2.65% | -31.03% | -23.98% |
| EPS Diluted | -390.77% | -274.24% | -630.14% | -383.78% | 85.33% |
| Normalized Diluted EPS | 32.62% | 56.67% | -2.79% | -27.91% | -18.88% |
| Average Basic Shares Outstanding | 109.57% | 126.28% | 121.69% | 90.80% | 55.51% |
| Average Diluted Shares Outstanding | 104.41% | 119.32% | 113.59% | 92.29% | 59.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |